Yan Tristan D, Black Deborah, Savady Renaldo, Sugarbaker Paul H
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA.
Ann Surg Oncol. 2007 Feb;14(2):484-92. doi: 10.1245/s10434-006-9182-x. Epub 2006 Oct 12.
The efficacy of cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for patients with pseudomyxoma peritonei (PMP) remains to be established.
Searches for all relevant studies prior to March 2006 were performed on six databases. Two reviewers independently appraised each study using a predetermined protocol. The quality of each study was assessed. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies.
Ten most recent updates from each institution were included for appraisal and data extraction. There were no randomized controlled trials or comparative studies. All included articles were observational studies without control groups. Five studies were relatively large series (n>or=100). Two studies had relatively long-term follow-up (48 months and 52 months). The median follow-up in the remaining eight studies was shorter than 3 years (range 19-35 months). The median survival ranged from 51 to 156 months. The 1-, 2-, 3- and 5-year survival rates varied from 80 to 100%, 76 to 96%, 59 to 96% and 52 to 96%, respectively. The overall morbidity rate varied from 33 to 56%. The overall mortality rates ranged from 0 to 18%.
This study reviewed current evidence on CRS and PIC for PMP. Only observational studies were available for evaluation, which demonstrated some promising long-term results, as compared to historical controls. Due to the rarity of this disease, a well-designed prospective multi-institutional study would be meaningful.
减瘤手术（CRS）联合围手术期腹腔内化疗（PIC）治疗腹膜假黏液瘤（PMP）患者的疗效仍有待确定。
在2006年3月之前对六个数据库进行了所有相关研究的检索。两名评价者使用预定方案独立评价每项研究。评估每项研究的质量。通过叙述性综述并完整列出所有纳入研究的结果来综合临床疗效。
纳入了各机构的10篇最新更新文章进行评价和数据提取。没有随机对照试验或比较研究。所有纳入文章均为无对照组的观察性研究。5项研究为相对大样本系列（n≥100）。2项研究有相对长期的随访（48个月和52个月）。其余8项研究的中位随访时间短于3年（范围19 - 35个月）。中位生存期为51至156个月。1年、2年、3年和5年生存率分别为80%至100%、76%至96%、59%至96%和52%至96%。总体发病率为33%至56%。总体死亡率为0至18%。
本研究回顾了目前关于CRS和PIC治疗PMP的证据。仅有观察性研究可供评估，与历史对照相比显示出一些有前景的长期结果。由于该疾病罕见，设计良好的前瞻性多机构研究将具有意义。
